KZIA · Kazia Therapeutics Limited American Depositary Shares
View on chartInsiders & Stakes
| Josiah T. Austin 10% Owner | ▼ Sell | Open Market | 385,749 Shares held | 11/5/2013 | View profile |
| NOVOGEN LTD 10% Owner | ▼ Sell | Other | 0 Shares held | 12/3/2012 | View profile |
Transaction History
| Josiah T. Austin | ▼ Sell | Open Market | 23,922 | $144K | 11/5/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 25,400 | $153K | 11/4/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 1,100 | $7K | 10/29/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 37,409 | $231K | 10/28/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 62,591 | $386K | 10/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 90,025 | $559K | 10/15/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $4K | 2/26/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $4K | 2/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $5K | 2/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $5K | 2/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $5K | 2/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $5K | 2/25/2013 |
| Josiah T. Austin | ▼ Sell | Open Market | 500 | $5K | 2/25/2013 |
| NOVOGEN LTD | ▼ Sell | Other | 17,837,246 | $0 | 12/3/2012 |
| NOVOGEN LTD | ▼ Sell | Other | 4,827,000 | $0 | 11/20/2012 |
| NOVOGEN LTD | ▼ Sell | Other | 4,494,377 | $4.0M | 5/11/2012 |
| NOVOGEN LTD | ▲ Buy | Grant | 1,941,747 | $2.0M | 12/29/2011 |
| NOVOGEN LTD | ▲ Buy | Grant | 1,333,333 | $2.0M | 9/30/2011 |
| Josiah T. Austin | ▲ Buy | Open Market | 4,531,633 | $5.3M | 7/29/2008 |
| NOVOGEN LTD | ▲ Buy | Open Market | 2,908,295 | $6.3M | 7/28/2008 |
| Josiah T. Austin | ▲ Buy | Open Market | 7,000 | $34K | 3/25/2008 |
| Josiah T. Austin | ▲ Buy | Open Market | 435,039 | $3.4M | 9/10/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 200,000 | $1.7M | 7/10/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 24,100 | $202K | 6/28/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 7,000 | $60K | 6/22/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 4,183 | $35K | 6/21/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 15,244 | $125K | 6/20/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 10,800 | $91K | 6/19/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 1,685 | $14K | 6/18/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 4,000 | $34K | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 250 | $2K | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 250 | $2K | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 250 | $2K | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 100 | $857 | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 100 | $857 | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 650 | $6K | 6/14/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 10,000 | $89K | 6/13/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 2,573 | $23K | 6/12/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 8,000 | $75K | 6/8/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 1,005 | $9K | 6/7/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 8,940 | $82K | 6/6/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 7,700 | $74K | 6/1/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 10,000 | $92K | 5/30/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 1,900 | $17K | 5/29/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 7,200 | $66K | 5/25/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 10,000 | $91K | 5/24/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 5,200 | $49K | 5/23/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 8,000 | $74K | 5/21/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 5,000 | $47K | 5/17/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 13,875 | $133K | 5/16/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 1,510 | $15K | 4/10/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 23,000 | $228K | 4/4/2007 |
| Josiah T. Austin | ▲ Buy | Open Market | 8,914 | $89K | 4/2/2007 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial
Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial. Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.